Influenza virus vector for virotherapy
AssigneeBlue Sky Vaccines GmbH
InventorThomas Muster
Life of this patent
Estimating the term…
Abstract
The present invention provides a recombinant influenza virus vector comprising an NS gene encoding a truncated NS1 protein of at least 73 and up to 122 amino acids of the N-terminus of the respective wild type NS 1 protein, wherein said vector replicates in IFN-sensitive tumor cells and does not replicate in normal, non-tumor cells, and expresses a heterologous immunostimulatory polypetide. The invention further provides a pharmaceutical composition containing said influenza virus vector, its use for the treatment of cancer patients and methods for producing said influenza virus vaccine.
Claims16
A recombinant influenza A virus vector comprising an NS gene encoding a truncated NS1 protein consisting of 106 amino acids of the N-terminus of the respective wild type NS1 protein, wherein said vector:
- (i) replicates in IFN-sensitive tumor cells and in IFN-resistant tumor cells, and is attenuated in normal cells, and
- (ii) expresses a heterologous immunostimulatory polypeptide, wherein the heterologous polypeptide is a cytokine.
A recombinant influenza A virus vector comprising an NS gene encoding a truncated NS1 protein consisting of 106 amino acids of the N-terminus of the respective wild type NS1 protein, wherein said vector:
- (i) replicates in IFN-sensitive tumor cells and in IFN-resistant tumor cells, and is attenuated in normal cells, and
- (ii) expresses a heterologous immunostimulatory polypeptide, wherein the heterologous polypeptide is a cytokine selected from the group consisting of IL2, GM-CSF, IL-15,MIP 1alpha, and MIP3 alpha.
Dependencies are inferred from the claim text.